Stock info Edwards Lifesciences | Filter  Basic-Info

Edwards Lifesciences

The past year was a profitable year for the Edwards Lifesciences investors

Over the last 12 months, that were profitable period for the investors in Edwards Lifesciences, the stock gained around 15 percent. Over the past 5 years Edwards Lifesciences' stock rose at around 30 percent in value. Edwards Lifesciences's revenues between 2011 and 2015 were quite unstable and moved between 1,9 billion dollars and 2,49 billion dollars. Edwards Lifesciences's net results between 2011 and 2015 were very fluctuating and moved between 236,7 million dollars and 494,9 million dollars.

Edwards Lifesciences has her headquarter located in Irvine. Edwards Lifesciences primarily operates in the health care eq. & services sector. Michael A. Mussallemâ� is the company' CEO. The CFO of the company is Scott B. Ullemâ�. The past 10 years the (international) industry gained at around 102 percent. Over the past 5 years the sector is 64 percent higher.

Edwards Lifesciences didn't pay out any dividends (in the past 5 years).

Edwards Lifesciences' balance mostly financed with equity

At the end of 2015 the American company's balance sheet was worth 4,06 billion dollars. At the end of 2015 the total debt positon equaled 1,56 billion dollars. This is around 38,34 percent of the total balance sheet. Last year the health care company's price/earnings-ratio (PE) was around 27. So the investors valued the stock at 27 times 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a growth stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the health care company equaled around 16,8 billion dollars. At the end of 2015 the American company had around 215,4 million stocks listed on the exchanges.

All of Edwards Lifesciences's annual reports are stored here. More information about Edwards Lifesciences can be found it's website. .